{
  "openalex_id": "W2118978588",
  "doi": "https://doi.org/10.1158/1078-0432.ccr-09-1665",
  "title": "Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells",
  "abstract": "Abstract Purpose: A significant fraction of HER2-overexpressing breast cancers exhibit resistance to the HER2 antibody trastuzumab. Hyperactivity of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway confers trastuzumab resistance, and mammalian target of rapamycin (mTOR) is a major downstream effector of PI3K/AKT. Therefore, we examined whether mTOR inhibitors synergize with trastuzumab. Experimental Design: Immunocompetent mice bearing HER2+ mammary tumors were treated with trastuzumab, the mTOR inhibitor rapamycin, or the combination. Mice were imaged for tumor cell death using an optical Annexin-V probe and with [18F]FDG positron emission tomography. The signaling and growth effects of the mTOR inhibitor RAD001 on HER2+ cells treated with trastuzumab or lapatinib were evaluated. Results: Treatment of mice with trastuzumab plus rapamycin was more effective than single-agent treatments, inducing complete regression of 26 of 26 tumors. The combination induced tumor cell death (Annexin-V binding) and inhibited FDG uptake. Rapamycin inhibited mTOR and tumor cell proliferation as determined by phosphorylated S6 and Ki-67 immunohistochemistry, respectively. In culture, the combination of RAD001 plus trastuzumab inhibited cell growth more effectively than either drug alone. Trastuzumab partially decreased PI3K but not mTOR activity. Knockdown of TSC2 resulted in HER2-independent activation of mTOR and dampened the response to trastuzumab and lapatinib. Treatment with the HER2 inhibitor lapatinib decreased phosphorylated S6 and growth in TSC2-expressing cells but not in TSC2-knockdown cells. Conclusions: Inhibition of PI3K and mTOR are required for the growth-inhibitory effect of HER2 antagonists. These findings collectively support the combined use of trastuzumab and mTOR inhibitors for the treatment of HER2+ breast cancer. (Clin Cancer Res 2009;15(23):7266–76)",
  "authors": [
    {
      "display_name": "Todd W. Miller",
      "id": "A5080163243",
      "orcid": "https://orcid.org/0000-0001-8912-2909",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Todd W. Miller"
    },
    {
      "display_name": "James T. Forbes",
      "id": "A5113637630",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "James T. Forbes"
    },
    {
      "display_name": "Chirayu Shah",
      "id": "A5113661034",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Chirayu Shah"
    },
    {
      "display_name": "Shelby K. Wyatt",
      "id": "A5033328824",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Shelby K. Wyatt"
    },
    {
      "display_name": "H. Charles Manning",
      "id": "A5058291199",
      "orcid": "https://orcid.org/0009-0008-6938-4811",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "H. Charles Manning"
    },
    {
      "display_name": "Maria G. Olivares",
      "id": "A5031348379",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Maria G. Olivares"
    },
    {
      "display_name": "Violeta Sánchez",
      "id": "A5037252693",
      "orcid": "https://orcid.org/0000-0001-6639-9024",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Violeta Sanchez"
    },
    {
      "display_name": "Teresa C. Dugger",
      "id": "A5000701312",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Teresa C. Dugger"
    },
    {
      "display_name": "Nara de Matos Granja",
      "id": "A5041869770",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Nara de Matos Granja"
    },
    {
      "display_name": "Archana Narasanna",
      "id": "A5077523532",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Archana Narasanna"
    },
    {
      "display_name": "Rebecca S. Cook",
      "id": "A5102944784",
      "orcid": "https://orcid.org/0000-0001-7749-5361",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Rebecca S. Cook"
    },
    {
      "display_name": "J. Phillip Kennedy",
      "id": "A5103499613",
      "orcid": null,
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "J. Phillip Kennedy"
    },
    {
      "display_name": "Craig W. Lindsley",
      "id": "A5060483072",
      "orcid": "https://orcid.org/0000-0003-0168-1445",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Craig W. Lindsley"
    },
    {
      "display_name": "Carlos L. Arteaga",
      "id": "A5043946489",
      "orcid": "https://orcid.org/0000-0003-0870-9586",
      "institutions": [
        {
          "id": "I200719446",
          "display_name": "Vanderbilt University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Carlos L. Arteaga"
    }
  ],
  "publication_year": 2009,
  "publication_date": "2009-11-25",
  "type": "article",
  "cited_by_count": 132,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S183149254",
    "display_name": "Clinical Cancer Research",
    "issn_l": "1078-0432",
    "issn": [
      "1078-0432",
      "1557-3265"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "15",
  "issue": "23",
  "first_page": "7266",
  "last_page": "7276",
  "open_access": {
    "is_oa": true,
    "oa_status": "bronze",
    "oa_url": "https://aacrjournals.org/clincancerres/article-pdf/15/23/7266/1986718/7266.pdf",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C2779786085",
      "display_name": "Trastuzumab",
      "level": 4,
      "score": 0.91960037
    },
    {
      "id": "C86554907",
      "display_name": "PI3K/AKT/mTOR pathway",
      "level": 3,
      "score": 0.85874397
    },
    {
      "id": "C2777329042",
      "display_name": "Lapatinib",
      "level": 5,
      "score": 0.8526931
    },
    {
      "id": "C75217442",
      "display_name": "Protein kinase B",
      "level": 3,
      "score": 0.56068397
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.5551764
    },
    {
      "id": "C62112901",
      "display_name": "Cell growth",
      "level": 2,
      "score": 0.48208553
    },
    {
      "id": "C2779699572",
      "display_name": "Everolimus",
      "level": 2,
      "score": 0.47121802
    },
    {
      "id": "C43060935",
      "display_name": "RPTOR",
      "level": 4,
      "score": 0.46837315
    },
    {
      "id": "C2777921159",
      "display_name": "Sirolimus",
      "level": 2,
      "score": 0.41490233
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.40719643
    },
    {
      "id": "C98274493",
      "display_name": "Pharmacology",
      "level": 1,
      "score": 0.37335604
    },
    {
      "id": "C185592680",
      "display_name": "Chemistry",
      "level": 0,
      "score": 0.30384538
    },
    {
      "id": "C190283241",
      "display_name": "Apoptosis",
      "level": 2,
      "score": 0.28283063
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.2772245
    },
    {
      "id": "C530470458",
      "display_name": "Breast cancer",
      "level": 3,
      "score": 0.2581278
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.22476354
    },
    {
      "id": "C55493867",
      "display_name": "Biochemistry",
      "level": 1,
      "score": 0.071621776
    }
  ],
  "topics": [
    {
      "id": "T10755",
      "display_name": "HER2/EGFR in Cancer Research",
      "score": 0.9991
    },
    {
      "id": "T11016",
      "display_name": "Monoclonal and Polyclonal Antibodies Research",
      "score": 0.9989
    },
    {
      "id": "T10952",
      "display_name": "PI3K/AKT/mTOR signaling in cancer",
      "score": 0.998
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1078-0432.ccr-09-1665",
  "pdf_url": "https://aacrjournals.org/clincancerres/article-pdf/15/23/7266/1986718/7266.pdf",
  "retrieved_date": "2025-07-30T14:30:35.201249",
  "source_database": "OpenAlex"
}